跳至主要内容
临床试验/NCT03833570
NCT03833570已完成2 期

The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis

Hams Hamed Abdelrahman1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2018年1月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Changes in severity of oral mucositis at different time points along the study

研究概览

简要总结

The main aim of this study was to evaluate the effectiveness of melatonin in prevention of radiation induced oral mucositis clinically and biochemically.

详细描述

The study was designed as randomized, controlled, clinical trial. patients who were undergoing chemoradiation were divided into two groups: Group I: was given conventional treatment. Group II: was given melatonin therapy in combination with the conventional treatment.

All patients were clinically evaluated at the start the radiotherapy, three weeks and six weeks later for pain and oral mucositis severity. in addition, the total antioxidant capacity of the melatonin was evaluated at the start of the radiotherapy and six weeks later.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
25 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are going to receive radiotherapy as a treatment of head and neck cancer either as postoperative (adjuvant) therapy or definitive therapy.
  • Patients whose radiotherapy treatment planned dose is between 60-70 Gy.
  • Patients who had received chemotherapy prior to radiotherapy or are going to receive chemotherapy in concomitant to radiotherapy.

排除标准

  • Patients under Anticoagulants such as warfarin, heparin, or aspirin.
  • Patients under Fluvoxamine (Luvox) and Nifedipine medications.
  • Patients whose radiotherapy treatment planned dose is lower than 60 Gy.
  • Pregnant and lactating women.
  • Patients suffering from any uncontrolled systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction)
  • Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.

研究组 & 干预措施

Melatonin therapy

Experimental

Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment

Symptomatic treatment which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks

Symptomatic treatment dose: Three times a day for six weeks

干预措施: Miconaz oral gel (Drug)

Melatonin therapy

Experimental

Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment

Symptomatic treatment which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks

Symptomatic treatment dose: Three times a day for six weeks

干预措施: Rapid Release Capsules Melatonin, 10 mg (Dietary Supplement)

Melatonin therapy

Experimental

Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment

Symptomatic treatment which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks

Symptomatic treatment dose: Three times a day for six weeks

干预措施: BBC oral spray (Drug)

Melatonin therapy

Experimental

Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment

Symptomatic treatment which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks

Symptomatic treatment dose: Three times a day for six weeks

干预措施: Oracure gel (Drug)

Melatonin therapy

Experimental

Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment

Symptomatic treatment which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks

Symptomatic treatment dose: Three times a day for six weeks

干预措施: Alkamisr sachets (Other)

Conventional therapy

Active Comparator

Conventional therapy (symptomatic treatment) which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Dose: Three times a day for six weeks

干预措施: Miconaz oral gel (Drug)

Conventional therapy

Active Comparator

Conventional therapy (symptomatic treatment) which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Dose: Three times a day for six weeks

干预措施: BBC oral spray (Drug)

Conventional therapy

Active Comparator

Conventional therapy (symptomatic treatment) which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Dose: Three times a day for six weeks

干预措施: Oracure gel (Drug)

Conventional therapy

Active Comparator

Conventional therapy (symptomatic treatment) which included:

  • Miconaz oral gel
  • BBC oral spray
  • Oracure gel
  • Alkamisr sachets

Dose: Three times a day for six weeks

干预措施: Alkamisr sachets (Other)

结局指标

主要结局

Changes in severity of oral mucositis at different time points along the study

时间窗: up to 3 and 6 weeks

Oral mucositis will be evaluated by the World Health Organization (WHO) scale which record the extent and severity of oral mucositis at the third and sixth week after the first radiotherapy session. This scale combines both subjective and objective measures of oral mucositis. World Health Organization (WHO) scale for oral mucositis: * Grade 0 = No oral mucositis * Grade 1 = Erythema and Soreness * Grade 2 = Ulcers, able to eat solids * Grade 3 = Ulcers, requires liquid diet (due to mucositis) * Grade 4 = Ulcers, alimentation not possible (due to mucositis)

Changes in the total antioxidant capacity (TAC) in saliva at different time points along the study

时间窗: Baseline (day 0) and up to 6 weeks

TAC is an index that measures total capacity of antioxidants in biological fluids using Colorimetric Method. it can evaluate the antioxidant response against the free radicals produced by radiotherapy. Normal reference values for TAC in saliva: 0.3-1 mM/L Higher values than normal range indicate higher level of TAC Changes in the total antioxidant capacity were evaluated at the first day of radiotherapy session (baseline) and six weeks later

次要结局

  • Pain and discomfort severity at different time points along the study: Numeric Rating Scale(up to 3 and 6 weeks)

研究者

发起方
Hams Hamed Abdelrahman
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Hams Hamed Abdelrahman

Instructor of Dental Public Health

Alexandria University

研究点 (1)

Loading locations...

相似试验